|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61P 35/00 | (2006.01) |
| A61K 45/06 | (2006.01) | ||
| A61K 47/54 | (2017.01) |
| (11) | Number of the document | 3003489 |
| (13) | Kind of document | T |
| (96) | European patent application number | 14807006.3 |
| Date of filing the European patent application | 2014-06-04 | |
| (97) | Date of publication of the European application | 2016-04-13 |
| (45) | Date of publication and mention of the grant of the patent | 2021-08-18 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2014/040872 |
| Date | 2014-06-04 |
| (87) | Number | WO 2014/197569 |
| Date | 2014-12-11 |
| (30) | Number | Date | Country code |
| 201361831219 P | 2013-06-05 | US |
| (72) |
LEVITT, Daniel , US
|
| (73) |
CytRx Corporation ,
11726 San Vicente Blvd., Los Angeles, CA 90049,
US
|
| (54) | CYTOTOXIC AGENTS FOR THE TREATMENT OF CANCER |
| CYTOTOXIC AGENTS FOR THE TREATMENT OF CANCER |